Surgical Infections Flashcards
Temperature
<36 C or >38 C
HR
> 90 beats per minute
RR
> 20 breaths per minute
PaCO2
< 32 mmHg
WBC Count
<4000 or >12000 cells/mm3 or >10% immature forms
UTI
3-5 days
Pneumonia
7-10 days
Bacteremia
7-14 days
Penetrating gastrointestinal trauma
12-24 hours
Perforated or gangrenous appendicitis
3-5 days
Peritoneal soilage secondary to perforated viscus with moderate contamination
5-7 days
Extensive peritoneal soilage (feculent peritonitis) in the immunocompromised host
7-14 days
Only skin microbiota
Class I: Clean
Opened w/o significant spillage
Class II: Clean contaminated
Open accidental wounds
Class III: Contaminated
Traumatic wound + significant treatment delay
Class IV: Dirty
Necrotic tissue, purulent discharge
Class IV: Dirty
Introduction of bacteria due to major breaks in sterile technique (open cardiac massage)
Class III: Contaminated
Perforated viscus high degree of contamination
Class IV: Dirty
Hernia repair
Class I: Clean
Perforated diverticulitis
Class IV: Dirty
Breast biopsy specimen P device (mesh, valve)
Class I: Clean
Cholecystectomy
Class II: Clean contaminated
Elective GI surgery (not colon)
Class II: Clean contaminated
Penetrating abdominal trauma
Class III: Contaminated
Necrotizing soft
tissue infections
Class IV: Dirty
Large tissue injury
Class III: Contaminated
Enterotomy during bowel obstruction
Class III: Contaminated
Occurs when microbes invade normally sterile peritoneal cavity via hematogenous dissemination from distant source of infection or direct inoculation
Primary microbial peritonitis
Common among patients who retain large amounts of peritoneal fluid due to ascites and those treated for renal failure via peritoneal dialysis
Primary microbial peritonitis
Diffuse tenderness
Primary microbial peritonitis
Guarding without localized findings
Primary microbial peritonitis
Absence of pneumoperitoneum
Primary microbial peritonitis
Occurs subsequent to contamination of the peritoneal cavity due to perforation or severe inflammation and infection of an intra-abdominal organ
Secondary microbial peritonitis
Poorly understood entity that is more common in immunosuppressed patients
Tertiary (Persistent) Peritonitis
Peritoneal host defences do not effectively clear or sequester the initial secondary microbial peritoneal infection
Tertiary (Persistent) Peritonitis
Develops in the absence of original visceral organ
Tertiary (Persistent) Peritonitis
Caused by manipulation of the biliary tract to treat a variety of diseases but nearly 50% of patients have no identifiable cause
Pyogenic liver abscess
Should be sampled and treated with a 4 to 6 week course of antibiotics
Small (< 1 cm), multiple abscesses
Parameters for antibiotic therapy and drain removal for larger abscesses:
- Clear evidence cavity collapse
- Output <10 - 20 mL/d
- No evidence of ongoing source of contamination
- Clinical condition improved
Dosage of metronidazole for amoebic liver abscess:
750 mg TID x 10 days
Current care includes staging with dynamic, contrast material enhanced helical CT scan to evaluate the extent of pancreatitis coupled with the use of one of several prognostic scoring systems.
Severe Acute Pancreatitis
Placed past the ligament of Treitz, associated with decreased development of infected necrosis → decreased gut translocation of bacteria
Nasojejunal feeding tubes
Dilation of the retroperitoneal drain tract
VARD (Video-Assisted Retroperitoneal Drainage)
Debridement of pancreatic bed
VARD (Video-Assisted Retroperitoneal Drainage)
Repeat debridement are performed as clinically indicated with most patients requiring multiple debridement.
VARD (Video-Assisted Retroperitoneal Drainage)
Culture of postoperative UTI SYMPTOMATIC patients:
> 104 CFU/mL microbes
Culture of postoperative UTI ASYMPTOMATIC patients:
> 105 CFU/mL microbes
Due to prolonged mechanical ventilation
Nosocomial Pneumonia
Infection associated with indwelling intravascular catheters
Bacteremia
Selected catheter infections due to low-virulence microbes such as Staphylococcus epidermidis can be effectively treated in approximately 50% to 60% of patients with a __________ course of an antibiotic, which should be considered when no other vascular access site exists
14- to 21-day
Central Venous Pressure (CVP)
8-12 mmHg
Mean Arterial Pressure
MAP
≥ 65 mmHg
Urine Output
≥ 0.5 mL/kg/h
Mixed Venous Oxygen
Saturation
65%
IV antibiotic therapy
1st hour after sepsis recognition
Broad spectrum
Penetration into presumed
source
Discontinue antibiotic
7-10 days
1 L; CVP = 8-12 mmHg
Crystalloid
First line of choice
Centrally administered
norepinephrine
Setting of myocardial
dysfunction
Dobutamine
Intravenous hydrocortisone dose
<300 mg/d
Septic shock hypotension
Intravenous hydrocortisone
Poor response to fluids and
vasopressors
Intravenous hydrocortisone
Hgb < 7.0 g/dL
RBC
Acute lung injury
VT 6 mL/kg body weight
Plateau pressure ≤ 30 cm H2O
Avoid lung collapse
Positive end-expiratory
pressure
Discontinue mechanical
ventilation
Weaning protocol
Prevent stress ulcer
Proton pump inhibitor
H2 blocker
Prevent DVT
Low does fractionated
heparin
Hospital-associated infection
MRSA
More common in chronically ill patients receiving multiple
courses of antibiotic
MRSA
MRSA produce a toxin knowns as:
Panton-Valentin leukocidin
make up an increasingly high percentage of surgical
site infections since they are resistant to commonly
employed prophylactic antimicrobial agents.
Panton-Valentin leukocidin
Produce a plasmid-mediated inducible β-lactamase.
Extended spectrum β-lactamase (ESBL)
Sensitive to first-, second-, or third- generation
cephalosporins with resistance to others
Extended spectrum β-lactamase (ESBL)
Use of this seemingly active agent leads to rapid induction of
resistance and failure of antibiotic therapy.
Extended spectrum β-lactamase (ESBL)
Treatment for ESBL:
Carbapenem
Resistance is transposon-mediated
Vancomycin-resistant strain of Enterococcus (VRSE)
Can transfer genetic material to S aureus in a host coinfected
with both organisms which can lead to
Vancomycin resistance in S aureus (VRSA)
Needlestick from a source with HIV-infected blood
0.3% estimated risk of transmission
Significantly decreased the risk of seroconversion
Antiretroviral Therapy (ART)
2-3-drug regimen
Raltegavir
Tenofovir/emtricitabine
develops in 75% to 80% of patients with
the infection
Chronic carrier state
occurs in three-fourths of patients who
develop chronic infection
Chronic liver disease
Seroconversion rate after accidental needlestick
1.8%
Treatment for HCV:
Ribavirin + Pegylated gamma interferon
United States halted BWA programs
Presidential Decree in 1971
Inhalational anthrax develops after a _________________.
1- to 6-day incubation period
Chest roentgenographic findings in Anthrax:
Widened mediastinum
Pleural effusions
Post exposure prophylaxis for anthrax:
Ciprofloxacin
Doxycycline
Amoxicillin
Treatment for anthrax:
ciprofloxacin, clindamycin, and
rifampin
To block production of toxin
Clindamycin
Penetrates into the central nervous system and
intracellular locations
Rifampin
Epidemic pneumonia with blood-tinged sputum if aerosolized
bacteria are used
Plague
Individuals who develop the following are suspected with
Bubonic plague:
- Painful enlarged lymph node lesions “bubo”
- Fever
- Severe malaise
- Exposure to fleas
Post exposure prophylaxis for plague:
Doxycycline
Treatment of the pneumonic or bubonic/septicemic form:
- Streptomycin
- Doxycycline
- Ciprofloxacin
- Levofloxacin
- Chloramphenicol
Prolonged viability has been demonstrated in scabs up to
_______ after collection
13 years
Incubation period for small pox:
10 to 12 days
Postexposure prophylaxis for smallpox:
Cidofovir
After inoculation, the organism proliferates within
macrophages
Tularemia
Treatment of inhalational tularemia
Aminoglycoside
Doxycycline and ciprofloxacin (Second-line agents)
Cardiovascular surgery
Cefazolin
Cefuroxime
Gastroduodenal areal small intestinel nonobstructed
Cefazolin
Biliary tract; open procedure, laparascopic high risk
Cefazolin Cefoxitin Cefotetan Ceftriaxone Ampicillin-sulbactam
Biliary tract; laparascopic low risk
None
Appendectomy, uncomplicated
Cefoxitin
Cefotetan
Cefazolin + Metronidazole
Colorectal surgery, obstructed small intestine
Cefazolin or Ceftriaxone Metronidazole Ertapenem Cefoxitin Cefotetan Ampicillin-Sulbactam
Head and neck; clean contaminated
Cefazolin or cefuroxime
Metronidazole
Ampicilin-Sulbactam
Neurosurgical procedures
Cefazolin
Orthopedic surgery
Cefazolin
Ceftriaxone
Breast, hernia
Cefazolin